ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Zeria Pharmaceutical Co., Ltd. ?
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 8.92% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 8.64% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 8.92% over the last 5 years
3
Flat results in Jun 26
- INTEREST(HY) At JPY 270.84 MM has Grown at 15.12%
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.24 times
4
With ROCE of 9.33%, it has a attractive valuation with a 1.09 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 0.79%, its profits have fallen by -8%
5
Underperformed the market in the last 1 year
- The stock has generated a return of 0.79% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 59.79%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Zeria Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zeria Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Zeria Pharmaceutical Co., Ltd.
-100.0%
-0.03
20.09%
Japan Nikkei 225
60.14%
2.04
29.37%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.92%
EBIT Growth (5y)
18.15%
EBIT to Interest (avg)
23.91
Debt to EBITDA (avg)
1.74
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.63
Tax Ratio
24.85%
Dividend Payout Ratio
25.55%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.30%
ROE (avg)
8.64%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.10
EV to EBIT
11.66
EV to EBITDA
6.88
EV to Capital Employed
1.09
EV to Sales
1.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.33%
ROE (Latest)
7.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at 8.12 %
RAW MATERIAL COST(Y)
Fallen by 0.53% (YoY
NET PROFIT(9M)
Higher at JPY 7,583.06 MM
CASH AND EQV(HY)
Highest at JPY 55,466.19 MM
-7What is not working for the Company
INTEREST(HY)
At JPY 270.84 MM has Grown at 15.12%
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.24 times
Here's what is working for Zeria Pharmaceutical Co., Ltd.
Debt-Equity Ratio
Lowest at 8.12 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Profit
At JPY 7,583.06 MM has Grown at 52.41%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
Cash and Eqv
Highest at JPY 55,466.19 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Net Profit
Higher at JPY 7,583.06 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Profit (JPY MM)
Raw Material Cost
Fallen by 0.53% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at JPY 2,288.99 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Zeria Pharmaceutical Co., Ltd.
Interest
At JPY 270.84 MM has Grown at 15.12%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Inventory Turnover Ratio
Lowest at 1.24 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
